Reuters logo
BRIEF-Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics
August 10, 2017 / 12:54 PM / 4 months ago

BRIEF-Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics

Aug 10 (Reuters) - Regen Biopharma Inc:

* Regen Biopharma Inc addresses potential impact of recent Bristol Myers Squibb’s $2.3 billion acquisition of IFM Therapeutics Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below